Amongst a climbing Central Line Associated Blood
Stream Infection ("CLABSI") rate across the United States, Covalon is releasing new
digital resources focused on the role of technology to strengthen
and reinforce infection prevention practices.
MISSISSAUGA, ON, Nov. 8, 2022
/CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV: COV) (OTCQX: CVALF), an advanced medical technologies
company, is ramping up awareness about rising Central Line
Associated Blood Stream Infection ("CLABSI") rates across the U.S.
with new digital resources designed to bring the standard infection
ratio for CLABSI down, specifically in pediatric patients.
Covalon is taking a stand against the significant rise in the
standard infection ratio for CLABSI through a new "CLABSI
Conscious" campaign geared to minimize human error, maintain safety
consistency, and empower frontline healthcare teams with the
technology they need to reduce CLABSIs in pediatric patients.
"The CDC has reported a 47% increase in CLABSIs in US hospitals
and a 65% increase in infections in intensive care units," says
Brian Pedlar, CEO of Covalon. "Sick
children don't deserve a CLABSI. While healthcare providers
continue to deal with unprecedented challenges, there are effective
and practical solutions at our fingertips to help all patients,
especially children to heal with their best chance for recovery and
comfort."
Covalon's new campaign focuses on the role that CLABSI-conscious
technology can play in maintaining safety consistency across
healthcare sites, teams, and procedures. The list of CLABSI
prevention practices at most hospitals is long, including highly
specialized sterilization protocols, hand hygiene mandates,
training toolkits, and more, but the role that advanced technology
plays is often overlooked. CLABSI-conscious technology can help
support CLABSI protocols by preventing human error, streamlining
workflows, and protecting patients using innovative
dual-antimicrobial infection prevention formulas like silver
combined with chlorhexidine.
As part of the CLABSI Conscious campaign, Covalon:
- Launched a brand new blog that provides resources for
healthcare professionals, patients and care providers on the role
technology plays in compassionate care, improving patient outcomes,
and infection prevention
- Renewed its social media presence on LinkedIn, Twitter,
Instagram, and Facebook with content that brings greater awareness
to the social, emotional, and economic cost of infections,
especially in vulnerable patients
- Is hosting an expert-led webinar on November 9 in collaboration with Paula Lamagna, RN, Education Coordinator,
Vascular Access Team, at Boston Children's Hospital to address
climbing CLABSI rates in pediatric patients. Webinar registration
details are below.
Webinar Details
CLABSI Prevention: New Technology to Address Rising CLABIS
Infection Rates in Pediatric Patients
Date: Thursday, November 10th at 1:00 pm EST, 10:00 am
PST
Registration: Click here to register
Hashtag: #InfectionPrevention
"Healthcare leaders around the world are aware of the toll that
frontline shortages, healthcare worker burnout, and the aftermath
of the COVID-19 pandemic have taken on the provision of healthcare
and patient outcomes," says Brian
Pedlar. "We are ramping up our resources, outreach,
partnerships, and plans to help frontline teams save time, stop
stressful setbacks from happening, and ultimately save lives."
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTQX Market under
the symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-launches-new-clabsi-conscious-campaign-to-help-children-heal-without-infections-301671662.html
SOURCE Covalon Technologies Ltd.